Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity – Campania Region
EXCLI Journal · 14.01.2026 · 25 · 191-203
DOI: 10.17179/excli2025-9067 ↗Kurz gefasst
Fachartikel in der Zeitschrift EXCLI Journal, online erschienen am 14.01.2026. Verfasst von Luigi Barrea und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Psicologia e Scienze della Salute, Università Telematica Pegaso, Naples, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is a growing public health concern, closely linked to metabolic and cardiovascular complications. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown substantial weight loss effects in clinical trials; however, real-world data, especially at lower doses, remain limited. This study aimed to evaluate the short-term effects of tirzepatide 2.5 mg and 5.0 mg on weight, metabolic parameters, and tolerability in adults with obesity in a real-world outpatient setting. This retrospective multicenter study included 70 adults with obesity but without type 2 diabetes, treated with tirzepatide between January and June 2025 in the Campania Region, Italy. Anthropometric and biochemical parameters were assessed at baseline. Follow-up data were collected at dose transitions: from 2.5 mg to 5.0 mg, and from 5.0 mg to 7.5 mg, allowing assessment of the effects of the 2.5 mg and 5.0 mg doses. Seventy participants were included (mean age 50.7 ± 10.2 years; 60 % female; BMI 37.5 ± 6.8 kg/m2). Treatment led to dose-dependent reductions in body weight, BMI, and waist circumference (p < 0.001 for all vs baseline and between doses). Significant improvements were observed in total cholesterol (p = 0.006 between doses), LDL cholesterol (p = 0.001), triglycerides (p < 0.001), prediabetes prevalence (p < 0.001 vs baseline; p = 0.002 between doses), fasting plasma glucose (p < 0.001 vs baseline; p < 0.001 between doses), insulin (p < 0.001 vs baseline; p < 0.001 between doses), HoMA-IR (p < 0.001 vs baseline; p < 0.001 between doses), AST (p = 0.012 vs baseline; p = 0.006 between doses), and ALT (p < 0.001 vs baseline; p = 0.007 between doses). Amylase increased significantly only at 5.0 mg (p = 0.016), while lipase remained unchanged. Renal function (eGFR) improved at both doses (p = 0.025 for 2.5 mg; p = 0.005 for 5.0 mg). Gastrointestinal adverse events were mild and similar between doses. In this real-world cohort, tirzepatide at 2.5 mg and 5.0 mg led to substantial improvements in weight and metabolic health, with good tolerability. These findings support its use in routine obesity care and justify further longitudinal research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Psicologia e Scienze della Salute, Università Telematica Pegaso, Naples, Italy.
- Department of Public Health, University of Naples Federico II, Naples, Italy.
- Division of Endocrinology, Department of Medicine, The University of Arizona College of Medicine, Tucson, AZ, USA.
- Centro Italiano per la cura e il Benessere del Paziente con Obesità (C.I.B.O), Unità di Endocrinologia, Diabetologia e Andrologia, Dipartimento di Medicina Clinica e Chirurgia, Università degli Studi di Napoli Federico…
- Unit of Abdominal Oncology, Division of Hepatobiliary Surgical Oncology,Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy.
- Ambulatorio di Obesiologia, Endocrinologia e Nutrizione Clinica - Centro Medico Polispecialistico DIGIMED, Naples, Italy.
Zitieren
APA
Barrea, L., Verde, L., Galasso, M., Patrone, R., Digitale, L., Limardi, A., Orio, M., Ragozzino, G., Digitale, L., Salvatore, V., Savoia, A., Savastano, S., Colao, A., & Muscogiuri, G. (2026). Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity – Campania Region. EXCLI Journal, 25, 191-203. https://doi.org/10.17179/excli2025-9067
Vancouver
Barrea L, Verde L, Galasso M, Patrone R, Digitale L, Limardi A, et al. Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity – Campania Region. EXCLI Journal. 2026;25:191-203. doi:10.17179/excli2025-9067
BibTeX
@article{Barrea2026,
author = {Barrea, Luigi and Verde, Ludovica and Galasso, Martina and Patrone, Renato and Digitale, Lucia and Limardi, Alessandro and Orio, Marcello and Ragozzino, Giovanni and Digitale, Luigi and Salvatore, Vittorio and Savoia, Antonella and Savastano, Silvia and Colao, Annamaria and Muscogiuri, Giovanna},
title = {Real-world data of tirzepatide in obesity management: a multicenter study by the Italian Society of Obesity – Campania Region},
journal = {EXCLI Journal},
year = {2026},
volume = {25},
pages = {191--203},
doi = {10.17179/excli2025-9067}
}
EUVIMED